Search - tctmd.com

Displaying 901 - 920 of 1010

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

News Daily News

La FDA Aprueba el Oclusor del FOP Amplatzer para la Prevención de ACV Recurrentes

Yael L. Maxwell

October 28, 2016

News Daily News

FDA 批准 PFO 封堵器用于预防中风复发

Yael L. Maxwell

October 28, 2016

News Daily News

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Yael L. Maxwell

October 28, 2016

News Daily News

Midlife Hypertension Linked to Late-Life Cognitive Decline

Leah Lawrence

October 11, 2016

News Features

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

Michael O'Riordan

October 05, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

Intensive SPRINT Blood Pressure Reduction Would Prevent 100,000 Deaths per Year

Michael O'Riordan

September 15, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

FDA Expands Indications for Two Endovascular Stroke Therapies

Todd Neale

September 06, 2016

News Daily News

FDA: Vascu-Guard Patch Associated With Bleeding, Death After Carotid Endarterectomy

Yael L. Maxwell

September 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Todd Neale

August 27, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Michael O'Riordan

August 26, 2016

News Daily News

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Michael O'Riordan

August 26, 2016

News Daily News

A pesar de la Muerte y las Penurias, la Cardiopatía Isquémica es la Principal Causa de Muerte en la ‘Primavera Árabe’

Michael O'Riordan

August 26, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

La FDA Aprueba el Oclusor del FOP Amplatzer para la Prevención de ACV Recurrentes

FDA 批准 PFO 封堵器用于预防中风复发

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Midlife Hypertension Linked to Late-Life Cognitive Decline

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

TCTMD’s Top 10 Most Popular Stories for September 2016

Intensive SPRINT Blood Pressure Reduction Would Prevent 100,000 Deaths per Year

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

FDA Expands Indications for Two Endovascular Stroke Therapies

FDA: Vascu-Guard Patch Associated With Bleeding, Death After Carotid Endarterectomy

TCTMD’s Top 10 Most Popular Stories for August 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

A pesar de la Muerte y las Penurias, la Cardiopatía Isquémica es la Principal Causa de Muerte en la ‘Primavera Árabe’

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content